Examples of 'xinafoate' in a sentence
Meaning of "xinafoate"
xinafoate (noun): A medication used to treat asthma and related respiratory conditions, typically taken via inhalation
Show more definitions
- 1-hydroxy-2-naphthoate radical of 1-hydroxy-2-naphthoic acid.
How to use "xinafoate" in a sentence
Basic
Advanced
xinafoate
Preferably salmeterol xinafoate is the only medicament.
Salmeterol will preferably be in the form of its xinafoate salt.
Salmeterol xinafoate and fluticasone propionate.
A particularly preferred combination is fluticasone propionate and salmeterol xinafoate.
Use in relation to salmeterol xinafoate is also preferred.
Salmeterol xinafoate is also of particular interest.
A preferred combination comprises salmeterol xinafoate and fluticasone propionate.
Salmeterol xinafoate and ethanol are combined to form a solution.
Micronisable form of salmeterol xinafoate.
Combinations of salmeterol xinafoate and beclomethasone dipropionate are preferred.
An example of such a combination is fluticasone propionate and salmeterol xinafoate.
Particulate salmeterol xinafoate in suspension in.
Salmeterol xinafoate may be prepared in two polymorphic forms known as Form I and Form II.
Preferably said combination comprises salmeterol xinafoate and fluticasone propionate.
Combinations of salmeterol xinafoate with fluticasone propionate or ipratropium bromide are of particular interest.
See also
Preferably the formulation contains salmeterol xinafoate as the sole medicament.
The amount of salmeterol xinafoate used in the various formulation is expressed as salmeterol base.
A particularly preferred combination comprises salmeterol xinafoate salt and fluticasone propionate.
R-salmeterol xinafoate was obtained by crystallisation from diethylether.
For example an aqueous solution of salmeterol xinafoate is spray dried on budesonide particles.
A process according to claim 1 wherein the substance is salmeterol xinafoate.
Fluticasone propionate and salmeterol xinafoate are of particular interest when used therapeutically in combination.
A process according to claim 7 wherein salmeterol is present as its xinafoate salt.
Especially preferred are compositions comprising salmeterol xinafoate and lactose in the form of multicomponent particles.
An assembly according to claim 5, wherein the medicament comprises salmeterol xinafoate.
Animal studies with salmeterol xinafoate have shown embryofoetal toxicity only at high exposure levels.
In a preferred embodiment, the pharmaceutically acceptable salt of salmeterol is salmeterol xinafoate.
Alternatively salmeterol xinafoate may be employed as the Form I polymorph.
A process as claimed in claim 14 wherein the inhalation compound is salmeterol xinafoate.
Salmeterol xinafoate Dimethicone.
The physical properties of the novel micronisable salmeterol xinafoate obtained are,.
In rats, salmeterol xinafoate is excreted in the milk.
A formulation as claimed in any one of claims 1 to 3 wherein the medicament is salmeterol xinafoate.
Furthermore, the xinafoate salt does not show any hydration or salvation.
A still further subject are the spray-dried coated salmeterol xinafoate particles.
Salmeterol xinafoate prepared using the present invention shows superior stage 2 deposition.
More particularly, the invention relates to novel crystalline forms of salmeterol xinafoate.
Formulations of salmeterol xinafoate in hydrofluoroalkane propellant will typically deliver 25 ug drug per actuation.
A formulation as claimed in claim 1 or claim 2 wherein salmeterol is present as the xinafoate salt.
Unless otherwise indicated, micronized salmeterol xinafoate was used in the preparation of the particles.
A pharmaceutical powder composition according to claim 6, wherein the medicament is salmeterol xinafoate.
A formulation according to claim 14 which contains salmeterol xinafoate in combination with fluticasone propionate.
A formulation according to any one of claims 1 to 6 wherein the medicament is salmeterol xinafoate.
On settling, the salmeterol xinafoate flocculated and extensively partitioned into the hexane layer.
A container as claimed in claim 1 or claim 2 wherein salmeterol xinafoate is the only medicament.
Suspending the coated salmeterol xinafoate particles obtained in stage ( b ) in the liquefied propellant gas.
In embodiments of the invention, the formulation comprises salmeterol xinafoate and fluticasone propionate.
The salmeterol xinafoate was precipitated at 300 bar from acetone.
A process according to claim 16 wherein the substance is a mixture of fluticasone propionate and salmeterol xinafoate.
The container is filled with a suspension of salmeterol xinafoate in liquid propellant HFA134a.
